GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Return-on-Tangible-Asset

IRIDEX (IRIDEX) Return-on-Tangible-Asset

: -36.95% (As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. IRIDEX's annualized Net Income for the quarter that ended in Dec. 2023 was $-11.84 Mil. IRIDEX's average total tangible assets for the quarter that ended in Dec. 2023 was $32.04 Mil. Therefore, IRIDEX's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -36.95%.

The historical rank and industry rank for IRIDEX's Return-on-Tangible-Asset or its related term are showing as below:

IRIX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -31.24   Med: -22   Max: 27.2
Current: -27.23

During the past 13 years, IRIDEX's highest Return-on-Tangible-Asset was 27.20%. The lowest was -31.24%. And the median was -22.00%.

IRIX's Return-on-Tangible-Asset is ranked worse than
67.59% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: -1.84 vs IRIX: -27.23

IRIDEX Return-on-Tangible-Asset Historical Data

The historical data trend for IRIDEX's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.43 -20.56 -14.34 -17.79 -26.89

IRIDEX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.30 -21.58 -30.61 -21.13 -36.95

Competitive Comparison

For the Medical Devices subindustry, IRIDEX's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRIDEX Return-on-Tangible-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where IRIDEX's Return-on-Tangible-Asset falls into.



IRIDEX Return-on-Tangible-Asset Calculation

IRIDEX's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-9.57/( (39.348+31.829)/ 2 )
=-9.57/35.5885
=-26.89 %

IRIDEX's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-11.84/( (32.258+31.829)/ 2 )
=-11.84/32.0435
=-36.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


IRIDEX  (NAS:IRIX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


IRIDEX Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of IRIDEX's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


IRIDEX (IRIDEX) Business Description

Traded in Other Exchanges
N/A
Address
1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Executives
Nandini Devi director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp 10 percent owner 75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp 10 percent owner 111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous director C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda director 402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer officer: COO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne director
Robert A Gunst director
David Bruce director, officer: President and CEO 1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum director
Romeo R Dizon other: Vice President and Controller 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043